Yuwei He

Yuwei He

Auto-generated profile, based on publicly available information

Yuwei He

Shandong Provincial Clinical Research Center for Immune Diseases and Gout, Shandong Provincial Clinical Medical Center for Gout, the Affiliated Hospital of Qingdao University Qingdao China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2024 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
HQHan Qi
Han Qi
MSMingshu Sun
Mingshu Sun
RTRobert Terkeltaub
Robert Terkeltaub
Tony R. MerrimanTony R. Merriman
Tony R. Merriman
HCHaibing Chen
Haibing Chen
CLChanggui Li
Changgui Li

20 February 2024 in Arthritis Care & Research
Verified
Journal Article
Closed access
XXXiaomei Xue
Xiaomei Xue
MSMingshu Sun
Mingshu Sun
FYFei Yan
Fei Yan
NDNicola Dalbeth
Nicola Dalbeth
YHYuwei He
Yuwei He
CLChanggui Li
Changgui Li

28 August 2024 in Arthritis & Rheumatology
Verified
Journal Article
Open access
AJAichang Ji
Aichang Ji
YSYang Sui
Yang Sui
XXXiaomei Xue
Xiaomei Xue
XJXiapeng Ji
Xiapeng Ji
WSWenrui Shi
Wenrui Shi
CLChanggui Li
Changgui Li
Objective: Mechanisms underlying the adolescent‐onset and early‐onset gout are unclear. This study aimed to discover variants associated with early‐onset gout.Methods: We conducted whole‐genome sequencing in a discovery adolescent‐onset gout cohort of 905 individuals (gout onset 12 to 19 years) to discover common and low‐frequency single‐nucleotide variants (SNVs) associated with gout. Candidate common SNVs were genotyped in an early‐onset gout cohort of 2,834 individuals (gout onset ≤30 years old), and meta‐analysis was performed with the discovery and replication cohorts to identify loci associated with early‐onset gout. Transcriptome and epigenomic analyses, quantitative real‐time polymerase chain reaction and RNA sequencing in human peripheral blood leukocytes, and knock‐down experiments in human THP‐1 macrophage cells investigated the regulation and function of candidate gene RCOR1.Results: In addition to ABCG2, a urate transporter previously linked to pediatric‐onset and early‐onset gout, we identified two novel loci (Pmeta < 5.0 × 10−8): rs12887440 (RCOR1) and rs35213808 (FSTL5‐MIR4454). Additionally, we found associations at ABCG2 and SLC22A12 that were driven by low‐frequency SNVs. SNVs in RCOR1 were linked to elevated blood leukocyte messenger RNA levels. THP‐1 macrophage culture studies revealed the potential of decreased RCOR1 to suppress gouty inflammation.Conclusion: This is the first comprehensive genetic characterization of adolescent‐onset gout. The identified risk loci of early‐onset gout mediate inflammatory responsiveness to crystals that could mediate gouty arthritis. This study will contribute to risk prediction and therapeutic interventions to prevent adolescent‐onset gout.

9 November 2023 in Arthritis Care & Research
Verified
Journal Article
Open access
YHYuwei He
Yuwei He
XXXiaomei Xue
Xiaomei Xue
NDNicola Dalbeth
Nicola Dalbeth
RTRobert Terkeltaub
Robert Terkeltaub
YCYing Chen
Ying Chen
MSMingshu Sun
Mingshu Sun
Objective: To assess post‐COVID‐19 vaccination gout flare risk with differing baseline flare burden.Methods: We prospectively studied gout patients with infrequent or frequent flares, defined as ≤1 flare/year or ≥2 flares/year, respectively. COVID‐19 vaccine‐naive patients managed with urate‐lowering therapy between February and June 2021 were included and voluntarily decided on vaccination. Participants were followed for 12 weeks after enrollment or first vaccine dose. Gout flares and risk factors were compared between groups.Results: Of 530 participants, 308 (58.1%) had infrequent flares and 222 (41.9%) had frequent flares at baseline, with 248 (142 infrequent and 106 frequent) receiving two‐dose COVID‐19 vaccination. Vaccination increased cumulative flare incidence at 12 weeks in the infrequent but not the frequent flare group (26.1% vs 10.8%, P = 0.001, compared with 60.4% vs 65.5%, P = 0.428). Flare incidence in the final 4 weeks of observation decreased significantly only in the vaccinated infrequent flare group (4.3% vs 12.0%, P = 0.017). Multivariable analyses showed that vaccination (odds ratio [OR] 2.82, 95% confidence interval [95% CI] 1.50–5.30, P = 0.001), flare in the preceding year (OR 1.95, 95% CI 1.03–3.71, P = 0.04), and body mass index (OR 1.09, 95% CI 1.01–1.19, P = 0.03) were independently associated with increased flare risk in the infrequent flare group. Baseline serum urate (mg/dl) was an independent risk factor in the frequent flare group (OR 1.23, 95% CI 1.05–1.45, P = 0.012).Conclusion: COVID‐19 vaccination was associated with increased early gout flares only in patients with previously infrequent flares. image

13 March 2026 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
WSWenyan Sun
Wenyan Sun
LXLingfang Xu
Lingfang Xu
HCHaibing Chen
Haibing Chen
MSMingshu Sun
Mingshu Sun
ZLZhiqiang Li
Zhiqiang Li
CLChanggui Li
Changgui Li
Objective: This study investigated that serum metabolomics, before urate‐lowering therapy (ULT) initiation, could serve as a biomarker for responsiveness to colchicine prophylaxis in patients with gout commencing treat‐to‐target ULT. Methods: We studied a multicenter prospective cohort (n = 409) initiating treat‐to‐target ULT plus colchicine prophylaxis. Untargeted metabolomics were measured at enrollment. We defined putative colchicine response or colchicine nonresponse as no flare or one or more flares, respectively, during six months after first colchicine dose. Cox regression and machine learning models defined the metabolomic signatures associated with reported flare activity on colchicine prophylaxis in the cohort. Results: In our cohort, 36.9% participants experienced at least one flare. Many inflammation‐related metabolites were differentially abundant in the recurrent flare group and correlated with recurrent flare risk. A significant association was found between a four‐metabolite risk score and gout flare activity (adjusted hazard ratio 3.21, 95% confidence interval [CI] 2.24–4.59), independent of the adjusted clinical factors. The machine learning model, which incorporated the top‐ranked metabolites selected by multivariable methods with unbiased variable selection along with traditional clinical factors, reached an area under the receiver operating characteristic of 0.771 (95% CI 0.713–0.828) and 0.724 (95% CI 0.611–0.837) for predicting flare risk in the discovery and validation cohort, respectively. Conclusion: Metabolomic profile–defined inflammation status was associated with gout flare outcomes in ULT initiators receiving colchicine prophylaxis. Identification of these novel metabolomic predictive signatures before ULT could potentially help optimize clinical decision‐making for flare prophylaxis colchicine dosing and duration in the first six months after initiation of treat‐to‐target ULT in gout. image

14 June 2023 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
XXXiaomei Xue
Xiaomei Xue
FYFei Yan
Fei Yan
KGKai Guo
Kai Guo
YHYuwei He
Yuwei He
CLChanggui Li
Changgui Li